On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading →
KEI Notes on the Clinical Studies for Imbruvica (Ibrutinib) KEI Briefing Note 2023:3 October 2, 2023 James Love KEI-BN-2023-3
Notes on the Preclinical Development of Imbruvica (Ibrutinib) KEI Briefing Note 2023:4 October 2, 2023 Arianna Schouten KEI-BN-2023-4
Mismatch between the cost to perform pediatric extension trials and the cost to the public of the six month extension of the drug monopoly KEI Briefing Note 2023:2 September 20, 2023 James Love, Manon Ress and Claire Cassedy KEI-BN-2023-2
The National Institute of Health (NIH) recently held an all-day workshop titled, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.” KEI Director James Love participated in the July 31st workshop, speaking on the panel on “How NIH… Continue Reading →
Canadian Experience with Compulsory Licensing under the Canadian Access to Medicines Regime KEI Briefing Note 2021:2 31 March 2021 Arianna Schouten PDF available here: KEI-Briefing-Note-2021-2-CAMR-Canadian-Compulsory-Licensing
Bayh-Dole Act and difference between March-In Rights and the world wide royalty free rights in patents KEI Briefing Note 2017:1 When the United States federal government funds research that results in patents, it obtains rights, either directly or through contracts,… Continue Reading →